Detection Technology Plc half-yearly report January-June 2026
Detection Technology Plc company announcement 6 August 2026 at 09:00 (EEST)
DETECTION TECHNOLOGY PLC HALF-YEARLY REPORT JANUARY-JUNE 2026
Detection Technology Q2 2026: Growth continued, driven by medical applications
April-June 2026 highlights
- Net sales increased by 5.1% to EUR 25.6 million (24.4)
- Net sales of Americas increased by 14.8% to EUR 1.7 million (1.5)
- Net sales of APAC (Asia-Pacific) increased by 1.8% to EUR 18.5 million (18.2)
- Net sales of EMEIA (Europe, Middle East, India and Africa) increased by 14.8% to EUR 5.4 million (4.7)
- Net sales of industrial applications decreased by -6.4% to EUR 5.2 million (5.6)
- Net sales of medical applications increased by 21.3% to EUR 12.8 million (10.6)
- Net sales of security applications decreased by -7.9% to EUR 7.6 million (8.2)
- Operating profit (EBITA) was EUR 1.8 million (1.7)
- Operating margin (EBITA-%) was 7.1% of net sales (7.0%)
- Return on net assets (RONA, 12-month rolling) was 19.9% (26.8%)
January-June 2026 highlights
- Net sales increased by 9.1% to EUR 50.9 million (46.6)
- Net sales of Americas increased by 21.4% to EUR 2.9 million (2.4)
- Net sales of APAC increased by 5.6% to EUR 36.1 million (34.2)
- Net sales of EMEIA increased by 18.0% to EUR 11.9 million (10.1)
- Net sales of industrial applications increased by 5.6% to EUR 9.8 million (9.3)
- Net sales of medical applications increased by 18.5% to EUR 25.4 million (21.4)
- Net sales of security applications decreased by -1.5% to EUR 15.7 million (15.9)
- Operating profit (EBITA) was EUR 4.2 million (3.1)
- Operating margin (EBITA-%) was 8.2% of net sales (6.7%)
UNAUDITED (Figures in parentheses refer to the corresponding period of the previous year.)
Business outlook
Detection Technology expects total net sales to grow year-on-year in Q3 and Q4 2026.
The geopolitical situation, new U.S. import tariffs, material constraints, and price competition create uncertainty.
Detection Technology aims to increase its sales by at least 10% per annum and to achieve an operating margin (EBITA) of 15% in the medium term.
President and CEO, Hannu Martola:
“In Q2, we continued to grow, driven by medical imaging applications and flat panel detector (TFT) sales. Sales increased by double digits in the EMEIA region and the Americas, while sales in APAC grew only modestly due to weak demand in China's security and industrial markets. It was particularly encouraging to see growth beginning to emerge in both sales and the order book for TFT in Western markets, especially in industrial applications.
Medical sales grew by double digits, supported by strong global demand for computed tomography (CT) applications. We also made progress in the medical TFT market. Our production facility in India received regulatory approval, and we commenced customer deliveries from the site.
Sales in security applications declined. Sales increased in Western markets and elsewhere in Asia outside China, where demand for line scan solutions remained weak and the deployment of aviation CT systems has been postponed. Our position and market share in security applications remain strong, particularly in the CT segment.
Sales of line scan solutions for industrial applications declined due to the quarter-to-quarter variability typical of this business. In contrast, sales of flat panel detectors increased across all geographic markets. The expansion of our product portfolio, new customer projects, and growing demand from the battery and defense industries support the continued growth of TFT sales.
Our profitability improved slightly compared to the reference period. In particular, the product mix, weighted towards medical CT solutions, and the introduction of a production process designed to strengthen our competitiveness weighed on our results.
In our DT2030 strategy, flat panel detectors are expected to deliver the largest share of growth and account for one-third of new sales. We have made good progress and secured new business for our new large-area flat panel products, particularly in industrial applications, where demand from 3D imaging in the battery industry and defense applications is driving our growth. To enable this growth, we have invested in our production operations in Finland and a new facility in Shanghai. Product development projects for new line scan, CT and cargo imaging applications are progressing, supporting growth particularly in Western markets while improving our cost competitiveness, especially in the APAC region. We are planning to transition to IFRS reporting at the end of the financial year, which will improve the comparability of our financial reporting with that of our international peers.
We expect our total net sales to increase in both Q3 and Q4 2026. In Q3, we expect sales in medical and industrial applications to increase, while sales in security applications are expected to decline due to continued softness in the Chinese market and demand fluctuations in the EMEIA region. Geographically, we expect growth to continue in APAC and the Americas, while sales in EMEIA are expected to decline as part of the sales shifts to the APAC region.”
Key figures
| (EUR 1,000) | 4-6/2026 | 4-6/2025 | 1-6/2026 | 1-6/2025 | 1-12/2025 |
| Net sales | 25,606 | 24,372 | 50,870 | 46,621 | 101,023 |
| Change in net sales, % | 5.1% | -6.6% | 9.1% | -4.5% | -6.0% |
| EBITA | 1,830 | 1,702 | 4,181 | 3,101 | 9,255 |
| EBITA, % | 7.1% | 7.0% | 8.2% | 6.7% | 9.2% |
| R&D costs | 2,823 | 3,146 | 5,595 | 5,781 | 11,266 |
| R&D costs, % of net sales | 11.0% | 12.9% | 11.0% | 12.4% | 11.2% |
| Cash flow from operating activities | -610 | 458 | -4,028 | 1,897 | 3,885 |
| Net interest-bearing debt at end of period | -8,497 | -19,794 | -8,497 | -19,794 | -20,473 |
| Investments | 3,280 | 1,144 | 3,689 | 1,548 | 2,965 |
| Return on net assets (RONA), % | 19.9% | 26.8% | 19.9% | 26.8% | 20.4% |
| Gearing, % | -10.6% | -27.2% | -10.6% | -27.2% | -26.1% |
| Earnings per share, EUR | 0.11 | 0.07 | 0.24 | 0.11 | 0.44 |
| Earnings per share (diluted), EUR | 0.11 | 0.07 | 0.24 | 0.11 | 0.44 |
| Number of shares at the end of the period | 14,655,630 | 14,655,630 | 14,655,630 | 14,655,630 | 14,655,630 |
| Weighted average number of shares outstanding | 14,655,630 | 14,655,630 | 14,655,630 | 14,655,730 | 14,655,680 |
| Weighted average number of shares outstanding, diluted | 14,655,630 | 14,655,630 | 14,655,630 | 14,657,943 | 14,656,787 |
Q2 2026 webcast
Hannu Martola, the President and CEO of Detection Technology, will present the Q2 and January–June 2026 financial performance and events to analysts, investors, and media at a webcast. The live webcast in English will begin on 6 August 2026 at 13:00 (EEST).
A link to the webcast is available on the company's website (investors, webcasts). A recording of the webcast will be available later on the same webcasts page.
This release is a summary of Detection Technology’s half-yearly report January–June 2026. The complete report can be found attached to the release and on the company's website.
Board of Directors, Detection Technology Plc
Further information
President and CEO Hannu Martola will be available for interviews and further information on the release date at 9:00-11:00 (EEST).
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company’s Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company’s solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company’s shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com